Xeris Biopharma Holdings, Inc.

Xeris Biopharma reported a net loss of $(31.1) million for Q2 2026, primarily due to a $(30.8) million loss on debt extinguishment related to its 2028 Convertible Notes. Despite this, total revenue grew 28.7% to $92.1 million for the quarter, driven by strong Recorlev sales. The company's stockholders' equity shifted to a deficit of $(9.7) million as of June 30, 2026, following the debt-related activities.

Xeris Biopharma Holdings, Inc. reported strong second quarter 2026 financial results, with total revenue increasing 29% year-over-year to $92.1 million and net product revenue growing 34% to $91.0 million. This growth was primarily driven by an 81% surge in Recorlev net revenue to approximately $57 million. The company tightened its full-year 2026 total revenue guidance to $385 million to $390 million, reflecting confidence in its business trajectory. Despite a net loss of $31.1 million due to a one-time non-cash charge related to Convertible Notes exchange agreements, Adjusted EBITDA improved to $19.3 million. Key business highlights included a Notice of Allowance for a new Keveyis patent extending protection through at least 2039 and the elimination of all 2028 Convertible Notes.

Xeris Biopharma Holdings, Inc. announced the completion of previously disclosed exchange transactions and a separate conversion of its 8.00% Convertible Senior Notes due 2028. The company exchanged approximately $23 million in principal amount of notes for 5.0 million shares of common stock and $23 million in cash. Additionally, a holder converted $10.5 million in notes into 3.6 million shares, resulting in no 2028 Notes remaining outstanding.

Xeris Biopharma Holdings, Inc. announced significant changes to its Board of Directors. The company appointed Dr. Nerissa Kreher as a new Class III director, expanding the Board from seven to eight members, effective July 1, 2026. Additionally, CEO John Shannon was named Chairman of the Board, succeeding Marla Persky, who will transition to the role of Lead Independent Director. Dr. Kreher brings extensive experience as a physician-scientist and biotech executive, particularly in rare diseases.

Xeris Biopharma Holdings, Inc. announced privately negotiated exchange agreements with certain noteholders to retire approximately $23 million in aggregate principal amount of its 8.00% Convertible Senior Notes due 2028. The exchange consideration will consist of cash, representing the principal amount, and shares of the company's common stock, determined by a 21-trading day volume-weighted average price. This transaction is expected to reduce outstanding notes by 69% to $10.5 million and generate approximately $2 million in annual interest savings, with closing anticipated around July 15, 2026.

Xeris Biopharma Holdings, Inc. reported a significant financial turnaround for the first quarter of 2026, achieving a net income of $2.23 million compared to a net loss of $9.22 million in the prior year. Total revenue increased by 38.3% to $83.13 million, driven primarily by strong growth in Recorlev sales. The company also generated positive cash flow from operating activities, a substantial improvement from the previous year's cash burn. Basic net income per common share was $0.01.

Xeris Biopharma reported strong first-quarter 2026 financial results, with total revenue increasing 38% year-over-year to $83.1 million. This growth was primarily driven by a 43% rise in total product revenue, notably Recorlev net revenue which nearly doubled to $49.8 million. The company achieved a net income of $2.2 million, a significant improvement from a net loss in the prior year, and tightened its full-year 2026 total revenue guidance to $380 million to $390 million.

Dr. Jeffrey Sherman will retire from Xeris Biopharma's Board of Directors, effective at the 2026 Annual Meeting of Stockholders. Dr. Sherman, who joined the board in 2021 and served on the Compensation and Nominating & Corporate Governance Committees, is not seeking re-election. His decision was not due to any disagreement with the company. Concurrently, the Board approved reducing its size from eight to seven directors.